Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study.
Saved in:
| Title: | Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study. |
|---|---|
| Authors: | Beer TM; Knight Cancer Institute, Oregon Health and Science University, Portland, OR 98239, United States., George DJ; Duke Cancer Institute, Duke University Shool of Medicine, Durham, NC, United States., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, United States., Winters-Stone K; Knight Cancer Institute, Oregon Health and Science University, Portland, OR 98239, United States.; Division of Oncological Sciences, School of Medicine, Oregon Health and Science University, Portland, OR, United States., Wefel JS; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Verholen F; Bayer Consumer Care, Basel, Switzerland., Srinivasan S; Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, United States., Ortiz J; Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, United States., Morgans AK; Dana-Farber Cancer Institute, Boston, MA, United States. |
| Source: | The oncologist [Oncologist] 2025 Jul 04; Vol. 30 (7). |
| Publication Type: | Journal Article; Multicenter Study; Clinical Trial, Phase II; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyae287 |
